MIM
ODT

MetLife Investment Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

MetLife Investment Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,941
Closed -$252K – 2347
2020
Q2 		$252K Hold
5,941
– – ﹤0.01% 1763
2020
Q1 		$164K Hold
5,941
– – ﹤0.01% 1800
2019
Q4 		$193K Hold
5,941
– – ﹤0.01% 1995
2019
Q3 		$155K Buy
5,941
+1,821
+44% +$60.9K ﹤0.01% 2086
2019
Q2 		$151K Buy
+4,120
New +$98.7K ﹤0.01% 2187

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MetLife Investment Management's ODT Position: Q3 2020 in Review

MetLife Investment Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 5,941 shares — an estimated $252K sold.

MetLife Investment Management first reported a position in ODT in Q2 2019 and held it in 5 quarters. The position peaked at $252K in Q2 2020. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

  • MetLife Investment Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • MetLife Investment Management sold 5,941 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $252K.
  • MetLife Investment Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • MetLife Investment Management's Odonate Therapeutics, Inc. Common Stock position peaked at $252K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on MetLife Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.